🇺🇸 FDA
Pipeline program

Rifaximin

SIBOC

Phase 3 small_molecule terminated

Quick answer

Rifaximin for Decompensated Cirrhosis is a Phase 3 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Decompensated Cirrhosis
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials